Your session is about to expire
← Back to Search
Other
MBX 2109 (Part A) for Healthy Subjects
Phase 1
Waitlist Available
Research Sponsored by MBX Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 40 (part a) or day 60 (part b)
Awards & highlights
Study Summary
This trial is evaluating the safety and tolerability of a new drug called MBX 2109 given as a shot under the skin. The study will also look at how well the drug is absorbed and how it affects the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through day 40 (part a) or day 60 (part b)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 40 (part a) or day 60 (part b)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Measures
Secondary outcome measures
Measures 1
Measures 2
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: MBX 2109 (Part B)Experimental Treatment1 Intervention
Repeated ascending SC doses
Group II: MBX 2109 (Part A)Experimental Treatment1 Intervention
Single ascending SC doses
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MBX 2109 (Part A)
2021
Completed Phase 1
~80
MBX 2109 (Part B)
2021
Completed Phase 1
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
MBX BiosciencesLead Sponsor
1 Previous Clinical Trials
84 Total Patients Enrolled
Mary Jane Geiger, MD, PhDStudy DirectorMBX Biosciences
Share this study with friends
Copy Link
Messenger